Dragan B. Djordjevic, Ivan Tasić, Bojana Stamenković, Svetlana Kostić, Milan Lović

DOI Number
First page
Last page


Numerous studies have pointed to low adherence to statin, which decreases as time period from acute cardiovascular event elapses. The aim was to analyze the cause of not taking statin by patients who were referred to rehabilitation after coronary event. Study population and methods. The research included the total of 573 patients, average age 60.3, while 305 (53.1%) of them were patients who experienced the first cardiovascular event. The stated research was conducted by means of a questionnaire and implied active participation of the researchers in terms of monitoring the possession and use of medication during rehabilitation. On arrival to rehabilitation, 98 (17.1%) patients did not have statin. They stated that they had never used statins before or that they stopped using them shortly after the event. This subgroup had significantly unfavorable values of lipid parameters (p<0.001), abdominal obesity (p<0.01), physical inactivity (p<0.01), more comorbidities (p<0.001), more prescribed medications on daily level (p<0.05), lower education degree level (p<0.01) and lower monthly income (p<0.001). Independent factors for not taking statin were: female gender, low monthly income and large number of comorbidities (R = 0.291, R2 = 0.85, adjusted R2 = 0.80, std. error of the estimate = 0.36151; p < 0.001). The patients themselves stated that the first reason for not taking statin was lack of financial funds (45.9%), while the second reason was normalization of laboratory results (21.4%). Three months after acute coronary event, 17.1% of patients in Serbia stopped taking statin. Lower adherence to statin closely correlates with female gender, low financial income and multiple comorbidities.


Statins, treatment, nonadherence, cardiovascular events, rehabilitation

Full Text:



The Scandinavian Simvastatin Survival Study Investigators. Randomised trials of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383–1389.

Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the Europen Society of Cardiology. Eur Heart J, 2008; 29:2909–2945.

Reiner Z, De Backer G, Fras Z, et al. Lipid lowering drugs therapy in patients with coronary heart disease from 24 European countries – findings from the EUROASPIRE IV study. Atherosclerosis 2016; 246:243–250.

Halvorsen S, Jortveit J, Hasvold P, Thuresson M, Oie E. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. BMC Cardiovasc Disord 2016; 16:115.

Mann DM, WoodwardM, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: A systematic review and meta-analysis. Ann Pharmacother 2010; 44:1410–1421.

Tasic I, Lazarevic G, Kostic S, Djordjevic D, Simonovic D, Rihter M, et al. Administration and effect of secondary prevention measures in coronary heart disease patients from Serbia according to gender and cardiometabolic risk. Acta Cardiol 2010; 65(4):407–414.

Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013; 51(803):S11–S21.

Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline. Ann Intern Med 2014; 160:339–343.

Yang Q, Zhong Y, Gillespie C, et al. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study. BMJ Open 2017; 7:e011684.

Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014; 129(25 Suppl 2):S49–73.

Xie G, Sun Y, Myint PK, et al. Six-month adherence to statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis 2017; 16:155–162.

Kumbhani DJ, Steg G, Cannon CP, et al. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med 2013; 126:693–700.

Bansilal S, Castellano JM, Garrdio E, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomees. JACC 2016; 68(8):789–801.

Ruokonieml P, Korhonen MJ, Helin-Salmlaara A, et al. Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol 2011; 71(5):766–776.

Reddy A, Huseman TL, Canamucio A, et al. Patient and partner feedback reports to improve statin medication adherence: a randomized control trial. J Gen Intern Med 2017; 32(3):256–261.

Latry P, Molimard M, Dedieu B, Couffinhal T, Begaud B, Martin-Latry K. Adherence with statins in real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovasc Disord 2011; 11:46.

Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a real-wold population of patients at high cardiovascular risk. J Manag Care Spec Pharm 2016; 22(6):685–698.



  • There are currently no refbacks.

ISSN 0354-2017 (Print)

ISSN 2406-0526  (Online)